Post-Treatment Bone Marrow Residual Disease > 5% by Flow Cytometry Is Highly Predictive of Short Progression-Free and Overall Survival in Patients With Waldenström's Macroglobulinemia

Clinical Lymphoma, Myeloma and Leukemia

Volumn 11, Issue 1, 2011, Pages 168-171

  Garcia Sanz R ^a,b   Ocio, E M ^a,b   Caballero, A ^a   Magalhaes R J P ^a   Alonso, J ^a   Lopez Anglada L ^a   Villaescusa, T ^a   Puig, N ^a   Hernandez J M ^c   Fernandez Calvo J ^c   Aguilar, A ^c   Martin A ^c   Lopez R ^c   Paiva, B ^a   Orfao, A ^b   Vidriales, B ^a   San Miguel, J F ^a,b   del Carpio, D ^d  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^b Centro de Investigacion del Cancer   (Spain)

^c UNIVERSITY OF SALAMANCA   (Spain)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD19 ANTIGEN;

AGED; ARTICLE; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; PATHOLOGY; PROGNOSIS; WALDENSTROEM MACROGLOBULINEMIA;

AGED; AGED, 80 AND OVER; ANTIGENS, CD19; BONE MARROW; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; WALDENSTROM MACROGLOBULINEMIA;

MLCS; MLOWN;

EID: 84856320264     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2011.n.040     Document Type: Article

References (16)

1. Weber, D, Treon, SP, Emmanouilides, C, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 (2003), 127–131.
2. Kimby, E, Treon, SP, Anagnostopoulos, A, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 6 (2006), 380–383.
3. Gertz, MA, Abonour, R, Heffner, LT, et al. Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 147 (2009), 677–680.
4. Gertz, MA, Anagnostopoulos, A, Anderson, K, et al. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 30 (2003), 121–126.
5. Treon, SP, Branagan, AR, Hunter, Z, et al. Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 15 (2004), 1481–1483.
6. Ghobrial, IM, Fonseca, R, Greipp, PR, et al. Initial immunoglobulin M ‘flare' after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 101 (2004), 2593–2598.
7. Tedeschi, A, Benevolo, G, Varettoni, M, et al. Final results of the phase II multicenter italian study of immunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) for symptomatic Waldenstrom's macroglobulinemia. Haematologica, 94(s2), 2009, 404a.
8. Leleu, X, Moreau, AS, Weller, E, et al. Serum immunoglobulin free light chain correlates with tumor burden markers in Waldenstrom macroglobulinemia. Leuk Lymphoma, 2008, 1–4.
9. Treon, SP, How I treat Waldenstrom macroglobulinemia. Blood 114 (2009), 2375–2385.
10. San Miguel, JF, Vidriales, MB, Ocio, E, et al. Immunophenotypic analysis of Waldenstrom's macroglobulinemia. Semin Oncol 30 (2003), 187–195.
11. Paiva, B, Vidriales, MB, Cervero, J, et al. Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. Blood 112 (2008), 4017–4023.
12. Paiva, B, Vidriales, MB, Perez, JJ, et al. Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients. Haematologica 94 (2009), 1599–1602.
13. Treon, S, Ioakimidis, T, Hanzis, C, et al. Progression free survival is predicated by categorical response, and supports the attainment of VGPR/CR as an objective for long term disease control in Waldenstrom's macroglobulinemia. Blood, 114, 2009, 4993.
14. Tedeschi, A, Benevolo, G, Varettoni, M, et al. Multicenter study of fludarabine, cyclophosphamiude and rituximab in untreated and previously treated Waldenström macxroglobulinemia. IWWM-6 1 (2010), 74–75.
15. Garcia-Sanz, R, Montoto, S, Torrequebrada, A, et al. Waldenstrom macroglobulinaemia: presenting features and outcome in a series with 217 cases. Br J Haematol 115 (2001), 575–582.
16. Rawstron, AC, Villamor, N, Ritgen, M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 21 (2007), 956–964.